Of note, ALCAM/CD6 interaction is a co-stimulatory pathway involved in T-cell activation (40, 41), and anti-CD6 clinical trials for RA are currently underway with promising outcomes (42, 43). The gene discussed is CD6; the disease is rheumatoid arthritis.